

## Fuljett ta' taghrif: Informazzjoni għall-utent

### **BIMERVAX® LP.8.1 emulsjoni għall-injezzjoni** **Vaċċin kontra l-COVID-19 (rikombinanti, imsahħah)** meracovatein

▼ Dan il-prodott mediċinali huwa suġġett għal monitoraġġ addizzjonali. Dan ser jippermetti identifikazzjoni rapida ta' informazzjoni ġdida dwar is-sigurtà. Inti tista' tgħin billi tirrapporta kwalunkwe effett sekondarju li jista' jkollok. Ara t-tmiem ta' sezzjoni 4 biex tara kif għandek tirrapporta effetti sekondarji.

#### **Aqra sew dan il-fuljett kollu qabel tirċievi dan il-vaċċin peress li fih informazzjoni importanti għalik.**

- Żomm dan il-fuljett. Jista' jkollok bżonn terġa' taqrah.
- Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispizjar jew lill-infermier tiegħek.
- Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek. Dan jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f'dan il-fuljett. Ara sezzjoni 4.

#### **F'dan il-fuljett**

1. X'inhu BIMERVAX LP.8.1 u għalxiex jintuża
2. X'għandek tkun taf qabel matirċievi BIMERVAX LP.8.1
3. Kif jingħata BIMERVAX LP.8.1
4. Effetti sekondarji possibbli
5. Kif taħžen BIMERVAX LP.8.1
6. Kontenut tal-pakkett u informazzjoni oħra

#### **1. X'inhu BIMERVAX LP.8.1 u għalxiex jintuża**

BIMERVAX LP.8.1 huwa vaċċin li jintuża biex jipprevjeni l-COVID-19 ikkawżat mill-virus tas-SARS-CoV-2.

BIMERVAX LP.8.1 jingħata lil individwi ta' età ta' 12-il sena u aktar.

Il-vaċċin jstimula lis-sistema immunitarja (id-difiżi naturali tal-ġisem) biex tipproduci antikorpi speċifiċi li jaħdmu kontra l-virus, filwaqt li jagħtu protezzjoni kontra l-COVID-19. L-ebda wiehed mill-ingredjenti f'dan il-vaċċin ma jista' jikkawża l-COVID-19.

#### **2. X'għandek tkun taf qabel ma tirċievi BIMERVAX LP.8.1**

##### **BIMERVAX LP.8.1 ma għandux jingħata**

- jekk inti allergiku għal sustanza attiva jew għal xi sustanza oħra ta' din il-mediċina (imniżżla fis-sezzjoni 6).

##### **Twissijiet u prekawzjonijiet**

Kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek qabel tirċievi BIMERVAX LP.8.1 jekk:

- inti qatt kellek reazzjoni allergika severa jew ta' periklu għall-hajja wara li rċivejt xi injezzjoni b'vaċċin ieħor
- inti qatt tak hażen waħda kwalunkwe injezzjoni b'labra,
- inti għandek temperatura għolja (aktar minn 38°C) jew infezzjoni severa. Madankollu, inti tista' tiehu t-tilqima tiegħek jekk ikollok ftit deni jew infezzjoni hafifa fil-pajpijiet tan-nifs bħal rih (mediċina antikoagulanti),

- inti għandek problemi ta' fsada, titbenġel malajr jew tuża mediċina biex tevita l-emboli tad-demmi;
- is-sistema immunitarja tiegħek ma taħdimx kif suppost (immunodeficijenza) jew inti qed tiegħu mediċini li jdgħajfu s-sistema immunitarja (bħal kortikosteroidi b'doża għolja, immunosoppressanti jew mediċini kontra l-kanċer).

Jekk xi waħda minn dawn ta' hawn fuq tapplika għalik (jew jekk ikollok xi dubju), kellek lit-tabib, lill-ispizjar jew lill-infermier tiegħek qabel ma tingħata BIMERVAX LP.8.1.

Bħal kull vaċċin ieħor, BIMERVAX LP.8.1 jista' ma jiprotegix b'mod sħiħ lil dawk kollha li jirċevuh, u mhux magħruf kemm inti ser iddum protett.

### **Tfal**

BIMERVAX LP.8.1 mhuwiex rakkomandat fi tfal li għandhom inqas minn 12-il sena. Attwalment ma hemm l-ebda informazzjoni disponibbli dwar l-użu ta' BIMERVAX LP.8.1 fi tfal iżgħar minn 12-il sena.

### **Mediċini oħra u BIMERVAX LP.8.1**

Għid lit-tabib, lill-ispizjar, jew lill-infermier tiegħek jekk qed tiegħu, ħadt dan l-aħħar jew tista' tiegħu xi mediċini jew vaċċini oħra.

### **Tqala u treddiġh**

Jekk inti tqila jew qed tredda', taħseb li tista' tkun tqila jew qed tippjana li jkollok tarbija, itlob il-parir tat-tabib, tal-ispizjar, jew tal-infermier tiegħek qabel tirċievi dan il-vaċċin.

### **Sewqan u thaddim ta' magni**

Xi wħud mill-effetti sekondarji ta' BIMERVAX LP.8.1 elemkati fis-sezzjoni 4 (Effetti sekondarji possibbli) jistgħu jnaqqsu b'mod temporanju l-hila tiegħek biex issuq u thaddem magni. Stenna sakemm jitlaq kwalunkwe effett tal-vaċċin qabel ma ssuq jew thaddem magni.

### **BIMERVAX LP.8.1 odium, potassium u polysorbate**

Dan il-vaċċin fih anqas minn 1 mmol sodium (23 mg) f'kull doża, jiġifieri essenzjalment "ħieles misodium".

Dan il-vaċċin fih anqas minn 1 mmol potassium (39 milligramma) f'kull doża ta' 0.5 ml, jiġifieri essenzjalment "ħieles mill-potassium".

Dan il-vaċċin fih 1.18 mg ta' polysorbate 80 f'kull doża. Polysorbates jistgħu jikkawżaw reazzjonijiet allergiċi. Għid lit-tabib tiegħek jekk għandek xi allergiji magħrufa.

## **3. Kif jingħata BIMERVAX LP.8.1**

### *Individwi ta' età ta' 12-il sena u aktar*

BIMERVAX LP.8.1 se jingħatalek bħala injezzjoni ta' 0.5 ml f'muskolu tal-parti ta' fuq tad-driegħ tiegħek.

Huwa rakkomandat li tirċievi BIMERVAX LP.8.1 bħala doża waħda mill-inqas 6 xhur wara doża preċedenti ta' vaċċin kontra l-COVID-19.

Wara l-injezzjoni, it-tabib, l-ispizjar jew l-infermier tiegħek se jharsuk għal madwar 15-il minuta biex jimmonitorjaw għal sinjali ta' reazzjoni allergika.

Jekk għandek aktar mistoqsijiet dwar l-użu ta' BIMERVAX LP.8.1, staqsi lit-tabib, lill-ispizjar jew lill-infermier tiegħek.

### *Individwi immunokompromessi*

Jekk is-sistema immunitarja tiegħek ma taħdimx kif suppost, jistgħu jingħataw doži addizzjonali f'konformità mar-rakkomandazzjonijiet uffiċjali.

## **4. Effetti sekondarji possibbli**

Bħal kull medicina oħra, dan il-vaċċin jista' tikkawża effetti sekondarji, għalkemm ma jidhrux f'kulhadd.

Il-biċċa l-kbira tal-effetti sekondarji jseħħu fi żmien 3 ijiem wara li tirċievi l-vaċċin u jgħaddu fi ftit jiem minn meta jidhru. Jekk is-sintomi jippersistu, ikkuntattja lit-tabib, lill-ispizjar jew lill-infermier tiegħek.

Ikseb attenzjoni medika urġenti jekk ikollok sintomi ta' reazzjoni allergika severa ftit wara t-tilqima. Sintomi bħal dawn jistgħu jinkludu:

- thossok li se jagħtik hass hażin jew tistordi
- tibdil fit-tahbit ta' qalbek
- qtugħ ta' nifs
- tharhir
- nefha f'xuftejk, f'wiċċek jew fi grizmejk
- nefhiet li jggegħluk thokk taht il-gilda (horriqija) jew raxx
- thossok imqalla (dardir) jew rimettar
- uġiġh fl-istonku

L-effetti sekondarji li ġejjin jistgħu jseħħu b'BIMERVAX LP.8.1:

### **Komuni hafna** (jistgħu jaffettwaw aktar minn persuna 1 minn kull 10)

- uġiġh ta' ras
- uġiġh fejn tingħata l-injezzjoni
- thossok għajjen hafna (gheja)
- uġiġh fil-muskoli

### **Komuni** (jistgħu jaffettwaw sa persuna 1 minn kull 10)

- ħmura, nefha jew sensittività fejn tingħata l-injezzjoni
- thossok ma tiflaħx (dardir) jew tkun imdardar (tirremetti)
- dijarea
- deni
- limfonodi mkabbra
- uġiġh taht l-abt

### **Mhux komuni** (jistgħu jaffettwaw sa persuna 1 minn kull 100)

- sirdat jew thoss li se jaqbdek id-deni
- sturdament
- ħakk fejn tkun ingħatat l-injezzjoni
- uġiġh fil-gogi
- thossok dgħajjed jew nuqqas ta' enerġija
- thossok bi nghan
- ħakk fil-gilda
- thossok ma tiflaħx b'mod ġenerali

### **Rari** (jistgħu jaffettwaw sa persuna 1 minn kull 1000)

- għaraq kiesaħ
- thoss affarijiet mhux tas-soltu fil-gilda, bħal tingiż jew thoss bħal insetti jigru (paresteżija)
- nuqqas ta' sens tas-sensittività, speċjalment fil-gilda (ipoesteżija)

- uġiġh addominali
- uġiġh meta tibra'
- reazzjonijiet allergiċi bħal ħorriqija, raxx jew ħakk
- tbenġil fejn tingħata l-injezzjoni
- sensitività eċċessiva fejn tkun ingħatat l-injezzjoni

**Mhux magħruf** (ma tistax tittiehed stima mid-data disponibbli, ibbażata fuq każ wiehed waqt provi kliniċi)

- infjammazzjoni tar-rita ta' barra tal-qalb (perikardite), li tista' tirriżulta fi qtugħ ta' nifs, palpatazzjonijiet jew uġiġh fis-sider

### **Rappurtar tal-effetti sekondarji**

Jekk ikollok xi effett sekondarju, kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek. Dan jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f'dan il-fuljett. Tista' wkoll tirrapporta effetti sekondarji direttament permezz tas-

ADR Reporting Website: <https://medicinesauthority.gov.mt/adrportal>

u tinkludi n-numru tal-lott/Lott jekk disponibbli. Billi tirrapporta l-effetti sekondarji tista' tgħin biex tiġi pprovduta aktar informazzjoni dwar is-sigurtà ta' dan il-vaċċin.

## **5. Kif taħzen BIMERVAX LP.8.1**

Żomm din il-medicina fejn ma tidhirx u ma tintlaħaqx mit-tfal.

It-tabib, l-ispizjar jew l-infermier tiegħek huma responsabbli għall-ħażna ta' dan il-vaċċin u għar-rimi b'mod korrett ta' kwalunkwe prodott li ma jkunx intuża. It-tagħrif li jmiss dwar il-ħażna, l-iskadenza, l-użu u l-immaniġġjar kif ukoll ir-rimi qed jingħata biss għall-professjonisti tal-kura tas-saħħa biss.

Tużax dan il-vaċċin wara d-data ta' meta jiskadi li tidher fuq it-tikketta wara JIS. Id-data ta' meta tiskadi tirreferi għall-aħħar ġurnata ta' dak ix-xahar.

Aħzen fi friġġ (2°C – 8°C). Tagħmlux fil-friża. Żomm il-kunjetti fil-kartuna ta' barra sabiex tilqa' mid-dawl.

Qabel l-użu, il-vaċċin jista' jinħareġ mill-friġġ darba għal perjodu massimu ta' 24 siegħa f'temperatura ta' mhux iktar minn 25°C.

L-informazzjoni dwar l-immaniġġjar hija deskritta fis-sezzjoni maħsuba għall-professjonisti tal-kura tas-saħħa fi tmiem il-fuljett ta' tagħrif.

Kull fdal tal-prodott mediċinali li ma jkunx intuża jew skart li jibqa' wara l-użu tal-prodott għandu jintrema kif jitolbu l-liġijiet lokali.

## **6. Kontenut tal-pakkett u informazzjoni ohra**

### **X'fih BIMERVAX LP.8.1**

- Doża waħda (0.5 ml) fiha 40 mikrogramma ta' meracovatein imsahħaħ b'SQBA.
- Meracovatein huwa omodimeru tal-fużjoni tad-dominju għall-irbit mar-riċettur (RBD) tal-proteina spika (S) rikombinanti tal-virus tas-SARS-CoV-2 (razza Omicron LP.8.1- LP.8.1) prodott permezz ta' teknoloġija rikombinanti tad-DNA.

- SQBA huwa inkluz f'dan il-vaċċin bhala aġġuvant biex jaċċellera u jtejjeb-effetti protettivi tal-vaċċin. Għal kull doża ta' 0.5 ml, SQBA fih: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) u ilma għall-injezzjonijiet.
- Is-sustanzi mhux attivi (eċċipjenti) l-oħra huma: disodium phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, potassium chloride u ilma għall-injezzjonijiet. BIMERVAX LP.8.1 fih potassium, sodium u polysorbate (ara sezzjoni 2).

### **Kif jidher BIMERVAX LP.8.1 u l-kontenut tal-pakkett**

Il-vaċċin huwa emulsjoni omogenja bajda għall-injezzjoni.

0.5 ml ta' emulsjoni hija pprovduta f'kunjett b'tapp tal-gomma u b'għatu tal-plastik tat-tip flip off.

Kull kunjett b'doża waħda fih doża waħda ta' 0.5 ml.

Daqsijiet tal-pakkett: 1, 10 jew 20 kunjett b'doża waħda.

### **Detentur tal-Awtorizzazzjoni għat-Tqeghid fis-Suq**

#### **Hipra Human Health, S.L.U.**

Avda. la Selva, 135  
17170 Amer (Girona)  
SPANJA

#### **Manifattur**

Laboratorios Hipra, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPANJA

### **Dan il-fuljett kien rivedut l-ahhar f' 05/2026**

### **Sorsi oħra ta' informazzjoni**

Informazzjoni dettaljata dwar din il-medicina tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Medicini: <https://www.ema.europa.eu>

Skennja l-kodiċi b'apparat mobbli biex tikseb il-fuljett ta' tagħrif f'lingwi differenti.



Jew żur il-URL: [www.hipracovidvaccine.com](http://www.hipracovidvaccine.com)

---

## **It-tagħrif li jmiss qed jinghata biss għall-professjonisti tal-kura tas-saħħa biss:**

Agħti BIMERVAX LP.8.1 ġol-muskoli, preferibbilment fil-muskolu deltojde tal-parti ta' fuq tad-driegħ.

### Traccabilità

Sabiex tittejjeb it-traccabilità tal-prodotti mediċinali bijoloġiċi, l-isem u n-numru tal-lott tal-prodott amministrat għandhom jiġu rrekordjati.

### Istruzzjonijiet dwar l-immaniġġjar u l-għoti

Tużax dan il-vaċċin wara d-data ta' meta jiskadi li tidher fuq it-tikketta wara JIS. Id-data ta' meta jiskadi tirreferi għall-aħħar ġurnata ta' dak ix-xahar.

Dan il-vaċċin għandu jiġi mmaniġġat minn professjonist fil-kura tas-saħħa bl-użu ta' tekniki asettici sabiex tiġi żgurata l-isterilità ta' kull doża.

### *Preparazzjoni għall-użu*

- Il-vaċċin jiġi lest biex jintuża.
- Vaċċin mhux miftuħ għandu jinħażen f' temperatura ta' 2°C sa 8°C u jinżamm fil-kaxxa ta' barra sabiex tilqa' mid-dawl.
- Immedjatament qabel l-użu, oħroġ il-kunjett tal-vaċċin mill-kartuna fil-frigġ.

### *Spezzjona l-kunjett*

- Dawwar il-kunjett bil-mod qabel ma tiġbed id-doża. Thawdux.
- Kull kunjett fih emulsjoni bajda u omogenja.
- Spezzjona viżwalment il-vaċċin għal frak u/jew telf tal-kulur qabel l-għoti. Tagħtix il-vaċċin jekk ikun hemm xi waħda minn dawn.

### *Agħti l-vaċċin*

- F'kull kunjett hija inkluża zieda fil-volum biex jiġi żgurat li tista' tiġi estratta kull doża ta' 0.5 mL. Armi kwalunkwe vaċċin li jifdal fil-kunjett.
- Doża waħda ta' 0.5 mL tingħbed f' labra sterili u f' siringa sterili biex tingħata permezz ta' injezzjoni ġol-muskoli, preferibbilment fil-muskolu deltojde tal-parti ta' fuq tad-driegħ.
- Thallatx il-vaċċin fl-istess siringa ma' kwalunkwe vaċċin ieħor jew prodotti mediċinali oħra.
- Tiġborx vaċċin żejjed minn bosta kunjetti.

### *Rimi*

- Kull fdal tal-prodott mediċinali li ma jkunx intuża jew skart li jibqa' wara l-użu tal-prodott għandu jintrema kif jitolbu l-liġijiet lokali.

## Fuljett ta' taghrif: Informazzjoni għall-utent

### **BIMERVAX® LP.8.1 emulsjoni għall-injezzjoni f'siringa mimlija għal-lest Vaċċin kontra l-COVID-19 (rikombinanti, imsahħah) meracovatein**

▼ Dan il-prodott mediċinali huwa suġġett għal monitoraġġ addizzjonali. Dan ser jippermetti identifikazzjoni rapida ta' informazzjoni ġdida dwar is-sigurtà. Inti tista' tgħin billi tirrapporta kwalunkwe effett sekondarju li jista' jkollok. Ara t-tmiem ta' sezzjoni 4 biex tara kif għandek tirrapporta effetti sekondarji.

**Aqra sew dan il-fuljett kollu qabel tirċievi dan il-vaċċin peress li fih informazzjoni importanti għalik.**

- Żomm dan il-fuljett. Jista' jkollok bżonn terġa' taqrah.
- Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispizjar jew lill-infermier tiegħek.
- Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek. Dan jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f'dan il-fuljett. Ara sezzjoni 4.

#### **F'dan il-fuljett**

1. X'inhum BIMERVAX LP.8.1 u għalxiex jintuża
2. X'għandek tkun taf qabel matirċievi BIMERVAX LP.8.1
3. Kif jingħata BIMERVAX LP.8.1
4. Effetti sekondarji possibbli
5. Kif taħžen BIMERVAX LP.8.1
6. Kontenut tal-pakkett u informazzjoni oħra

#### **1. X'inhum BIMERVAX LP.8.1 u għalxiex jintuża**

BIMERVAX LP.8.1 huwa vaċċin li jintuża biex jipprevjeni l-COVID-19 ikkawżat mill-virus tas-SARS-CoV-2.

BIMERVAX LP.8.1 jingħata lil individwi ta' età ta' 12-il sena u aktar.

Il-vaċċin jistimula lis-sistema immunitarja (id-difiżi naturali tal-ġisem) biex tipproduci antikorpi speċifiċi li jaħdmu kontra l-virus, filwaqt li jagħtu protezzjoni kontra l-COVID-19. L-ebda wiehed mill-ingredjenti f'dan il-vaċċin ma jista' jikkawża l-COVID-19.

#### **2. X'għandek tkun taf qabel ma tirċievi BIMERVAX LP.8.1**

##### **BIMERVAX LP.8.1 ma għandux jingħata**

- jekk inti allergiku għal sustanza attiva jew għal xi sustanza oħra ta' din il-mediċina (imnizzla fis-sezzjoni 6).

##### **Twissijiet u prekawzjonijiet**

Kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek qabel tirċievi BIMERVAX LP.8.1 jekk:

- inti qatt kellek reazzjoni allergika severa jew ta' periklu għall-hajja wara li rċivejt xi injezzjoni b'vaċċin ieħor
- inti qatt tak hażen waħda kwalunkwe injezzjoni b'labra,
- inti għandek temperatura għolja (aktar minn 38°C) jew infezzjoni severa. Madankollu, inti tista' tiehu t-tilqima tiegħek jekk ikollok ftit deni jew infezzjoni haġifa fil-pajpijiet tan-nifs bħal rih (mediċina antikoagulanti),

- inti għandek problemi ta' fsada, titbenġel malajr jew tuża mediċina biex tevita l-emboli tad-demem;
- is-sistema immunitarja tiegħek ma taħdimx kif suppost (immunodeficijenza) jew inti qed tieħu mediċini li jdgħajfu s-sistema immunitarja (bħal kortikosteroidi b'doża għolja, immunosoppressanti jew mediċini kontra l-kanċer).

Jekk xi waħda minn dawn ta' hawn fuq tapplika għalik (jew jekk ikollok xi dubju), kellek lit-tabib, lill-ispizjar jew lill-infermier tiegħek qabel ma tingħata BIMERVAX LP.8.1.

Bħal kull vaċċin ieħor, BIMERVAX LP.8.1 jista' ma jiprotegix b'mod sħiħ lil dawk kollha li jirċevuh, u mhux magħruf kemm inti ser iddum protett.

### **Tfal**

BIMERVAX LP.8.1 mhuwiex rakkomandat fi tfal li għandhom inqas minn 12-il sena. Attwalment ma hemm l-ebda informazzjoni disponibbli dwar l-użu ta' BIMERVAX LP.8.1 fi tfal iżgħar minn 12-il sena.

### **Mediċini oħra u BIMERVAX LP.8.1**

Għid lit-tabib, lill-ispizjar, jew lill-infermier tiegħek jekk qed tieħu, ħadt dan l-aħħar jew tista' tieħu xi mediċini jew vaċċini oħra.

### **Tqala u treddiġh**

Jekk inti tqila jew qed tredda', taħseb li tista' tkun tqila jew qed tippjana li jkollok tarbija, itlob il-parir tat-tabib, tal-ispizjar, jew tal-infermier tiegħek qabel tirċievi dan il-vaċċin.

### **Sewqan u thaddim ta' magni**

Xi wħud mill-effetti sekondarji ta' BIMERVAX LP.8.1 elemkati fis-sezzjoni 4 (Effetti sekondarji possibbli) jistgħu jnaqqsu b'mod temporanju l-hila tiegħek biex issuq u thaddem magni. Stenna sakemm jitlaq kwalunkwe effett tal-vaċċin qabel ma ssuq jew thaddem magni.

### **BIMERVAX LP.8.1 odium, potassium u polysorbate**

Dan il-vaċċin fih anqas minn 1 mmol sodium (23 mg) f'kull doża, jiġifieri essenzjalment "ħieles misodium".

Dan il-vaċċin fih anqas minn 1 mmol potassium (39 milligramma) f'kull doża ta' 0.5 ml, jiġifieri essenzjalment "ħieles mill-potassium".

Dan il-vaċċin fih 1.18 mg ta' polysorbate 80 f'kull doża. Polysorbates jistgħu jikkawżaw reazzjonijiet allergiċi. Għid lit-tabib tiegħek jekk għandek xi allergiji magħrufa.

## **3. Kif jingħata BIMERVAX LP.8.1**

### *Individwi ta' età ta' 12-il sena u aktar*

BIMERVAX LP.8.1 se jingħatalek bħala injezzjoni ta' 0.5 ml f'muskolu tal-parti ta' fuq tad-driegħ tiegħek.

Huwa rakkomandat li tirċievi BIMERVAX LP.8.1 bħala doża waħda mill-inqas 6 xhur wara doża preċedenti ta' vaċċin kontra l-COVID-19.

Wara l-injezzjoni, it-tabib, l-ispizjar jew l-infermier tiegħek se jharsuk għal madwar 15-il minuta biex jimmonitorjaw għal sinjali ta' reazzjoni allergika.

Jekk għandek aktar mistoqsijiet dwar l-użu ta' BIMERVAX LP.8.1, staqsi lit-tabib, lill-ispizjar jew lill-infermier tiegħek.

### *Individwi immunokompromessi*

Jekk is-sistema immunitarja tiegħek ma taħdimx kif suppost, jistgħu jingħataw doži addizzjonali f'konformità mar-rakkomandazzjonijiet uffiċjali.

## **4. Effetti sekondarji possibbli**

Bħal kull medicina oħra, dan il-vaċċin jista' tikkawża effetti sekondarji, għalkemm ma jidhrux f'kulhadd.

Il-biċċa l-kbira tal-effetti sekondarji jseħħu fi żmien 3 ijiem wara li tirċievi l-vaċċin u jgħaddu fi ftit jiem minn meta jidhru. Jekk is-sintomi jippersistu, ikkuntattja lit-tabib, lill-ispizjar jew lill-infermier tiegħek.

Ikseb attenzjoni medika urġenti jekk ikollok sintomi ta' reazzjoni allergika severa ftit wara t-tilqima. Sintomi bħal dawn jistgħu jinkludu:

- thossok li se jagħtik hass hażin jew tistordi
- tibdil fit-tahbit ta' qalbek
- qtugħ ta' nifs
- tharhir
- nefha f'xuftejk, f'wiċċek jew fi grizmejk
- nefhiet li jggegħluk thokk taht il-gilda (horriqija) jew raxx
- thossok imqalla (dardir) jew rimettar
- uġiġh fl-istonku

L-effetti sekondarji li ġejjin jistgħu jseħħu b'BIMERVAX LP.8.1:

### **Komuni hafna** (jistgħu jaffettwaw aktar minn persuna 1 minn kull 10)

- uġiġh ta' ras
- uġiġh fejn tingħata l-injezzjoni
- thossok għajjen hafna (gheja)
- uġiġh fil-muskoli

### **Komuni** (jistgħu jaffettwaw sa persuna 1 minn kull 10)

- ħmura, nefha jew sensittività fejn tingħata l-injezzjoni
- thossok ma tiflaħx (dardir) jew tkun imdardar (tirremetti)
- dijarea
- deni
- limfonodi mkabbra
- uġiġh taht l-abt

### **Mhux komuni** (jistgħu jaffettwaw sa persuna 1 minn kull 100)

- sirdat jew thoss li se jaqbdek id-deni
- sturdament
- ħakk fejn tkun ingħatat l-injezzjoni
- uġiġh fil-gogi
- thossok dgħajjef jew nuqqas ta' enerġija
- thossok bi ngħas
- ħakk fil-gilda
- thossok ma tiflaħx b'mod ġenerali

### **Rari** (jistgħu jaffettwaw sa persuna 1 minn kull 1000)

- għaraq kiesaħ
- thoss affarijiet mhux tas-soltu fil-gilda, bħal tingiż jew thoss bħal insetti jigru (paresteżija)
- nuqqas ta' sens tas-sensittività, speċjalment fil-gilda (ipoesteżija)

- uġiġh addominali
- uġiġh meta tibra'
- reazzjonijiet allergiċi bħal ħorriqija, raxx jew ħakk
- tbenġil fejn tingħata l-injezzjoni
- sensitività eċċessiva fejn tkun ingħatat l-injezzjoni

**Mhux magħruf** (ma tistax tittiehed stima mid-data disponibbli, ibbażata fuq każ wiehed waqt provi kliniċi)

- infjammazzjoni tar-rita ta' barra tal-qalb (perikardite), li tista' tirriżulta fi qtugħ ta' nifs, palpitazzjonijiet jew uġiġh fis-sider

### **Rappurtar tal-effetti sekondarji**

Jekk ikollok xi effett sekondarju, kellem lit-tabib, lill-ispizjar jew lill-infermier tiegħek. Dan jinkludi xi effetti sekondarji possibbli li mhuwiex elenkat f'dan il-fuljett. Tista' wkoll tirrapporta effetti sekondarji direttament permezz tas-

ADR Reporting Website: <https://medicinesauthority.gov.mt/adrportal>

u tinkludi n-numru tal-lott/Lott jekk disponibbli. Billi tirrapporta l-effetti sekondarji tista' tgħin biex tiġi pprovduta aktar informazzjoni dwar is-sigurtà ta' dan il-vaċċin.

## **5. Kif taħzen BIMERVAX LP.8.1**

Żomm din il-medicina fejn ma tidhirx u ma tintlaħaqx mit-tfal.

It-tabib, l-ispizjar jew l-infermier tiegħek huma responsabbli għall-ħażna ta' dan il-vaċċin u għar-rimi b'mod korrett ta' kwalunkwe prodott li ma jkunx intuża. It-tagħrif li jmiss dwar il-ħażna, l-iskadenza, l-użu u l-immaniġġjar kif ukoll ir-rimi qed jingħata biss għall-professjonisti tal-kura tas-saħħa biss.

Tużax dan il-vaċċin wara d-data ta' meta jiskadi li tidher fuq it-tikketta wara JIS. Id-data ta' meta tiskadi tirreferi għall-aħħar ġurnata ta' dak ix-xahar.

Aħzen fi friġġ (2°C – 8°C). Tagħmlux fil-friża. Żomm il-prodott fil-kartuna ta' barra sabiex tilqa' mid-dawl.

Qabel l-użu, il-vaċċin jista' jinħareġ mill-friġġ darba għal perjodu massimu ta' 24 siegħa f'temperatura ta' mhux iktar minn 25°C.

L-informazzjoni dwar l-immaniġġjar hija deskritta fis-sezzjoni maħsuba għall-professjonisti tal-kura tas-saħħa fi tmiem il-fuljett ta' tagħrif.

Kull fdal tal-prodott mediċinali li ma jkunx intuża jew skart li jibqa' wara l-użu tal-prodott għandu jintrema kif jitolbu l-liġijiet lokali.

## **6. Kontenut tal-pakkett u informazzjoni ohra**

### **X'fih BIMERVAX LP.8.1**

- Doża waħda (0.5 ml) fiha 40 mikrogramma ta' meracovatein imsahħaħ b'SQBA.
- Meracovatein huwa omodimeru tal-fużjoni tad-dominju għall-irbit mar-riċettur (RBD) tal-proteina spika (S) rikombinanti tal-virus tas-SARS-CoV-2 (razza Omicron LP.8.1- LP.8.1) prodott permezz ta' teknoloġija rikombinanti tad-DNA.

- SQBA huwa inkluz f'dan il-vaċċin b'hala aġġuvant biex jaċċellera u jtejjeb l-effetti protettivi tal-vaċċin. Għal kull doża ta' 0.5 ml, SQBA fih: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) u ilma għall-injezzjonijiet.
- Is-sustanzi mhux attivi (eċċipjenti) l-oħra huma: disodium phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, potassium chloride u ilma għall-injezzjonijiet. BIMERVAX LP.8.1 fih potassium, sodium u polysorbate (ara sezzjoni 2).

### **Kif jidher BIMERVAX LP.8.1 u l-kontenut tal-pakkett**

Il-vaċċin huwa emulsjoni omogenja bajda għall-injezzjoni.

0.5 ml ta' emulsjoni f'siringa mimlija għal-lest (hġieg tat-tip I) magħluq b'tapp tal-plaġer (gomma tal-chlorobutyl) u għatu integrat għat-tarf (gomma tal-polyisoprene) mingħajr labra.

Kull siringa mimlija għal-lest fiha doża waħda ta' 0.5 mL.

Daqsijiet tal-pakkett: 1 jew 10 siringi mimlija għal-lest.

### **Detentur tal-Awtorizzazzjoni għat-Tqeghid fis-Suq**

#### **Hipra Human Health, S.L.U.**

Avda. la Selva, 135  
17170 Amer (Girona)  
SPANJA

#### **Manifattur**

Laboratorios Hipra, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPANJA

### **Dan il-fuljett kien rivedut l-aħhar f' 05/2026**

### **Sorsi oħra ta' informazzjoni**

Informazzjoni dettaljata dwar din il-medicina tinsab fuq is-sit elettroniku tal-Aġenzija Ewropea għall-Medicini: <https://www.ema.europa.eu>

Skennja l-kodiċi b'apparat mobbli biex tikseb il-fuljett ta' tagħrif f'lingwi differenti.



---

## **It-tagħrif li jmiss qed jinghata biss għall-professjonisti tal-kura tas-saħħa biss:**

Agħti BIMERVAX LP.8.1 ġol-muskoli, preferibbilment fil-muskolu deltojde tal-parti ta' fuq tad-driegħ.

### Traccabilità

Sabiex tittejjeb it-traccabilità tal-prodotti mediċinali bijoloġiċi, l-isem u n-numru tal-lott tal-prodott amministrat għandhom jiġu rrekordjati.

### Istruzzjonijiet dwar l-immaniġġjar u l-ġhoti

Tużax dan il-vaċċin wara d-data ta' meta jiskadi li tidher fuq it-tikketta wara JIS. Id-data ta' meta jiskadi tirreferi għall-aħħar ġurnata ta' dak ix-xahar.

Dan il-vaċċin għandu jiġi mmaniġġat minn professjonist fil-kura tas-saħħa bl-użu ta' tekniki asettici sabiex tiġi żgurata l-isterilità ta' kull doża.

### *Preparazzjoni għall-użu*

- Il-vaċċin jiġi lest biex jintuża.
- Vaċċin mhux miftuħ għandu jinħażen f' temperatura ta' 2°C sa 8°C u jinżamm fil-kaxxa ta' barra sabiex tilqa' mid-dawl.
- Immedjatament qabel l-użu, ohroġ is-siringa mimlija għal-lest mill-kartuna.

### *Spezzjona s-siringa mimlija għal-lest*

- Dawwar is-siringa mimlija għal-lest bil-mod qabel ma tiġbed id-doża. Thawdux.
- Qabel l-użu, iċċekkja li s-sistema tal-għeluq hija ssikkata.
- Kull siringa mimlija għal-lest fiha emulsjoni bajda u omoġenja.
- Spezzjona viżwalment il-vaċċin għal frak u/jew telf tal-kulur qabel l-ġhoti. Tagħtix il-vaċċin jekk ikun hemm xi waħda minn dawn.
- Tagħtix il-vaċċin jekk is-siringa mimlija għal-lest ikollha l-ħsara.

### *Agħti l-vaċċin*

- Il-labar mhumiex inklużi fil-kartuni tas-siringa mimlija għal-lest.
- Uża labra sterili ta' gauge xieraq għall-injezzjoni ġol-muskoli.
- Bl-għatu għat-tarf wieqaf, neħhi l-għatu għat-tarf billi ddawwru fid-direzzjoni kontra l-arloġġ sakemm jinqala'. Neħhi l-għatu b' moviment bil-mod u stabbli. Tiġbdux waqt li tkun qed iddawwar.
- Qabbad il-labra billi ddawwarha fid-direzzjoni skont l-arloġġ sakemm il-labra tinqafel fuq is-siringa.
- Ħoll il-labra meta tkun lest għall-ġhoti.
- Agħti d-doża kollha ġol-muskoli.

### *Rimi*

- Kull fdal tal-prodott mediċinali li ma jkunx intuża jew skart li jibqa' wara l-użu tal-prodott għandu jintrema kif jitolbu l-liġijiet lokali.

## Package leaflet: Information for the user

### **BIMERVAX® LP.8.1 emulsion for injection COVID-19 vaccine (recombinant, adjuvanted) meracovatein**

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effect you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### **What is in this leaflet**

1. What BIMERVAX LP.8.1 is and what it is used for
2. What you need to know before you receive BIMERVAX LP.8.1
3. How BIMERVAX LP.8.1 is given
4. Possible side effects
5. How to store BIMERVAX LP.8.1
6. Contents of the pack and other information

#### **1. What BIMERVAX LP.8.1 is and what it is used for**

BIMERVAX LP.8.1 is a vaccine used to prevent COVID-19 caused by the SARS-CoV-2 virus.

BIMERVAX LP.8.1 is given to individuals 12 years of age and older.

The vaccine stimulates the immune system (the body's natural defences) to produce specific antibodies that work against the virus, giving protection against COVID-19. None of the ingredients in this vaccine can cause COVID-19.

#### **2. What you need to know before you receive BIMERVAX LP.8.1**

##### **BIMERVAX LP.8.1 should not be given**

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6).

##### **Warnings and precautions**

Talk to your doctor, pharmacist or nurse before receiving BIMERVAX LP.8.1 if:

- you have ever had a severe or life-threatening allergic reaction after receiving any other vaccine injection;
- you have ever fainted following any needle injection;
- you have a high temperature (over 38 °C) or severe infection. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold;
- you have bleeding problems, you bruise easily or you use a medicine to prevent blood clots (anticoagulant medicine);

- your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants, or cancer medicines).

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist, or nurse before you are given BIMERVAX LP.8.1.

As with any vaccine, BIMERVAX LP.8.1 may not fully protect all those who receive it, and it is not known how long you will be protected.

### **Children**

BIMERVAX LP.8.1 is not recommended for children aged below 12 years. Currently, there is no information available on the use of BIMERVAX LP.8.1 in children younger than 12 years of age.

### **Other medicines and BIMERVAX LP.8.1**

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines or vaccines.

### **Pregnancy and breastfeeding**

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before you receive this vaccine.

### **Driving and using machines**

Some of the side effects of BIMERVAX LP.8.1 listed in section 4 (Possible side effects) may temporarily reduce your ability to drive and use machines. Wait until any effects of the vaccine have worn off before you drive or use machines.

### **BIMERVAX LP.8.1 contains sodium, potassium and polysorbate**

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

This vaccine contains less than 1 mmol potassium (39 mg) per 0.5 mL dose, that is to say, essentially 'potassium-free'.

This vaccine contains 1.18 mg of polysorbate 80 in each dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

## **3. How BIMERVAX LP.8.1 is given**

### *Individuals 12 years of age and older*

BIMERVAX LP.8.1 will be given to you as 0.5 mL injection into a muscle of your upper arm.

It is recommended that you receive BIMERVAX LP.8.1 as a single dose at least 6 months after a previous dose of a COVID-19 vaccine.

After the injection, your doctor, pharmacist or nurse will watch over you for around 15 minutes to monitor for signs of an allergic reaction.

If you have any further questions on the use of BIMERVAX LP.8.1, ask your doctor, pharmacist or nurse.

### *Immunocompromised individuals*

If your immune system does not work properly additional doses may be administered in line with official recommendations.

#### 4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

Most of the side effects occur within 3 days of getting the vaccine and go away within a few days of appearing. If symptoms persist, contact your doctor, pharmacist or nurse.

Get urgent medical attention if you get symptoms of a severe allergic reaction shortly after vaccination. Such symptoms may include:

- feeling faint or light-headed
- changes in your heartbeat
- shortness of breath
- wheezing
- swelling of your lips, face, or throat
- itchy swelling under the skin (hives) or rash
- feeling sick (nausea) or vomiting
- stomach pain

The following side effects may occur with BIMERVAX LP.8.1:

**Very common** (may affect more than 1 in 10 people)

- headache
- pain where the injection is given
- feeling very tired (fatigue)
- muscle pain

**Common** (may affect up to 1 in 10 people)

- redness, swelling or tenderness where the injection is given
- feeling sick (nausea) or getting sick (vomiting)
- diarrhoea
- fever
- enlarged lymph nodes
- axillary pain

**Uncommon** (may affect up to 1 in 100 people)

- chills or feeling feverish
- dizziness
- itching where the injection is given
- joint pain
- feeling weak or lack of energy
- feeling sleepy
- itchy skin
- generally feeling unwell

**Rare** (may affect up to 1 in 1 000 people)

- cold sweating
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling of sensitivity, especially in the skin (hypoesthesia)
- abdominal pain
- pain when swallowing
- allergic reactions such as hives, rash or itching
- bruise where the injection is given

- hypersensitivity where the injection is given

**Not known** (cannot be estimated from available data, based on a single case during clinical trials)

- inflammation of the lining outside the heart (pericarditis), which can result in breathless, palpitations or chest pain

### **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via

ADR Reporting Website: <https://medicinesauthority.gov.mt/adrportal>

and include batch/Lot number if available. By reporting side effects, you can help provide more information on the safety of this vaccine.

## **5. How to store BIMERVAX LP.8.1**

Keep this medicine out of the sight and reach of children.

Your doctor, pharmacist, or nurse is responsible for storing this vaccine and disposing of any unused product correctly. The following information about storage, expiry, use and handling as well as disposal is intended for healthcare professionals.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vials in the outer carton in order to protect from light.

Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 24 hours at temperature not above 25°C.

Information on handling are described in the section intended for healthcare professionals at the end of the package leaflet.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **6. Contents of the pack and other information**

### **What BIMERVAX LP.8.1 contains**

- One dose (0.5 mL) contains 40 micrograms of meracovatein adjuvanted with SQBA.
- Meracovatein is SARS-CoV-2 virus recombinant spike (S) protein RBD fusion homodimer (Omicron LP.8.1 – LP.8.1 strain) produced by recombinant DNA technology.
- SQBA is included in this vaccine as an adjuvant to accelerate and improve the protective effects of the vaccine. SQBA contains per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.

- The other ingredients (excipients) are: disodium phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, potassium chloride and water for injections. BIMERVAX LP.8.1 contains potassium, sodium and polysorbate (see section 2).

### **What BIMERVAX LP.8.1 looks like and contents of the pack**

The vaccine is a white homogeneous emulsion for injection.

0.5 mL of emulsion is provided in a vial with a rubber stopper and a plastic flip-off top.

Each single dose vial contains 1 dose of 0.5 mL

Pack sizes: 1, 10 or 20 single dose vials.

### **Marketing Authorisation Holder**

Hipra Human Health, S.L.U.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

### **Manufacturer**

Laboratorios Hipra, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**This leaflet was last revised in 05/2026**

### **Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu>

Scan the code with a mobile device to get the package leaflet in different languages.



Or visit the URL: [www.hipracovidvaccine.com](http://www.hipracovidvaccine.com)

---

### **The following information is intended for healthcare professionals only:**

Administer BIMERVAX LP.8.1 intramuscularly, preferably into the deltoid muscle of the upper arm.

## Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

## Handling instructions and administration

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

This vaccine should be handled by a healthcare professional using aseptic techniques to ensure the sterility of each dose.

### *Preparation for use*

- The vaccine comes ready to use.
- Unopened vaccine should be stored at 2 °C to 8 °C and kept within the outer carton to protect from light.
- Immediately prior to use, remove the vaccine vial from the outer carton.

### *Inspect the vial*

- Gently swirl the vial before the dose withdrawal. Do not shake.
- Each vial contains a white and homogeneous emulsion.
- Visually inspect the vaccine for particulate matter and/or discolouration prior to administration. Do not administer the vaccine if any of these are present.

### *Administer the vaccine*

- An overfill is included in each vial to ensure that one dose of 0.5 mL can be extracted. Discard any remaining vaccine in the vial.
- One 0.5 mL dose is withdrawn into a sterile needle and sterile syringe to be administered by intramuscular injection, preferably in the deltoid muscle of the upper arm.
- Do not mix the vaccine in the same syringe with any other vaccines or medicinal products.
- Do not pool excess vaccine from multiple vials.

### *Disposal*

- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## Package leaflet: Information for the user

### **BIMERVAX® LP.8.1 emulsion for injection in pre-filled syringe COVID-19 vaccine (recombinant, adjuvanted) meracovatein**

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effect you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### **What is in this leaflet**

1. What BIMERVAX LP.8.1 is and what it is used for
2. What you need to know before you receive BIMERVAX LP.8.1
3. How BIMERVAX LP.8.1 is given
4. Possible side effects
5. How to store BIMERVAX LP.8.1
6. Contents of the pack and other information

#### **1. What BIMERVAX LP.8.1 is and what it is used for**

BIMERVAX LP.8.1 is a vaccine used to prevent COVID-19 caused by the SARS-CoV-2 virus.

BIMERVAX LP.8.1 is given to individuals 12 years of age and older.

The vaccine stimulates the immune system (the body's natural defences) to produce specific antibodies that work against the virus, giving protection against COVID-19. None of the ingredients in this vaccine can cause COVID-19.

#### **2. What you need to know before you receive BIMERVAX LP.8.1**

##### **BIMERVAX LP.8.1 should not be given**

- if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6).

##### **Warnings and precautions**

Talk to your doctor, pharmacist or nurse before receiving BIMERVAX LP.8.1 if:

- you have ever had a severe or life-threatening allergic reaction after receiving any other vaccine injection;
- you have ever fainted following any needle injection;
- you have a high temperature (over 38 °C) or severe infection. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold;
- you have bleeding problems, you bruise easily or you use a medicine to prevent blood clots (anticoagulant medicine);

- your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants, or cancer medicines).

If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist, or nurse before you are given BIMERVAX LP.8.1.

As with any vaccine, BIMERVAX LP.8.1 may not fully protect all those who receive it, and it is not known how long you will be protected.

### **Children**

BIMERVAX LP.8.1 is not recommended for children aged below 12 years. Currently, there is no information available on the use of BIMERVAX LP.8.1 in children younger than 12 years of age.

### **Other medicines and BIMERVAX LP.8.1**

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines or vaccines.

### **Pregnancy and breastfeeding**

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist, or nurse for advice before you receive this vaccine.

### **Driving and using machines**

Some of the side effects of BIMERVAX LP.8.1 listed in section 4 (Possible side effects) may temporarily reduce your ability to drive and use machines. Wait until any effects of the vaccine have worn off before you drive or use machines.

### **BIMERVAX LP.8.1 contains sodium, potassium and polysorbate**

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.

This vaccine contains less than 1 mmol potassium (39 mg) per 0.5 mL dose, that is to say, essentially 'potassium-free'.

This vaccine contains 1.18 mg of polysorbate 80 in each dose. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

## **3. How BIMERVAX LP.8.1 is given**

### *Individuals 12 years of age and older*

BIMERVAX LP.8.1 will be given to you as 0.5 mL injection into a muscle of your upper arm.

It is recommended that you receive BIMERVAX LP.8.1 as a single dose at least 6 months after a previous dose of a COVID-19 vaccine.

After the injection, your doctor, pharmacist or nurse will watch over you for around 15 minutes to monitor for signs of an allergic reaction.

If you have any further questions on the use of BIMERVAX LP.8.1, ask your doctor, pharmacist or nurse.

### *Immunocompromised individuals*

If your immune system does not work properly additional doses may be administered in line with official recommendations.

#### 4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

Most of the side effects occur within 3 days of getting the vaccine and go away within a few days of appearing. If symptoms persist, contact your doctor, pharmacist or nurse.

Get urgent medical attention if you get symptoms of a severe allergic reaction shortly after vaccination. Such symptoms may include:

- feeling faint or light-headed
- changes in your heartbeat
- shortness of breath
- wheezing
- swelling of your lips, face, or throat
- itchy swelling under the skin (hives) or rash
- feeling sick (nausea) or vomiting
- stomach pain

The following side effects may occur with BIMERVAX LP.8.1:

**Very common** (may affect more than 1 in 10 people)

- headache
- pain where the injection is given
- feeling very tired (fatigue)
- muscle pain

**Common** (may affect up to 1 in 10 people)

- redness, swelling or tenderness where the injection is given
- feeling sick (nausea) or getting sick (vomiting)
- diarrhoea
- fever
- enlarged lymph nodes
- axillary pain

**Uncommon** (may affect up to 1 in 100 people)

- chills or feeling feverish
- dizziness
- itching where the injection is given
- joint pain
- feeling weak or lack of energy
- feeling sleepy
- itchy skin
- generally feeling unwell

**Rare** (may affect up to 1 in 1 000 people)

- cold sweating
- unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)
- decreased feeling of sensitivity, especially in the skin (hypoesthesia)
- abdominal pain
- pain when swallowing
- allergic reactions such as hives, rash or itching
- bruise where the injection is given

- hypersensitivity where the injection is given

**Not known** (cannot be estimated from available data, based on a single case during clinical trials)

- inflammation of the lining outside the heart (pericarditis), which can result in breathless, palpitations or chest pain

### **Reporting of side effects**

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via ADR Reporting Website: <https://medicinesauthority.gov.mt/adrportal> and include batch/Lot number if available. By reporting side effects, you can help provide more information on the safety of this vaccine.

## **5. How to store BIMERVAX LP.8.1**

Keep this medicine out of the sight and reach of children.

Your doctor, pharmacist, or nurse is responsible for storing this vaccine and disposing of any unused product correctly. The following information about storage, expiry, use and handling as well as disposal is intended for healthcare professionals.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the product in the outer carton in order to protect from light.

Before use, the vaccine may be taken out of the refrigerator once for a maximum period of 24 hours at temperature not above 25°C.

Information on handling are described in the section intended for healthcare professionals at the end of the package leaflet.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **6. Contents of the pack and other information**

### **What BIMERVAX LP.8.1 contains**

- One dose (0.5 mL) contains 40 micrograms of meracovatein adjuvanted with SQBA.
- Meracovatein is SARS-CoV-2 virus recombinant spike (S) protein RBD fusion homodimer (Omicron LP.8.1 – LP.8.1 strain) produced by recombinant DNA technology.
- SQBA is included in this vaccine as an adjuvant to accelerate and improve the protective effects of the vaccine. SQBA contains per 0.5 mL dose: squalene (9.75 mg), polysorbate 80 (1.18 mg), sorbitan trioleate (1.18 mg), sodium citrate (0.66 mg), citric acid (0.04 mg) and water for injections.
- The other ingredients (excipients) are: disodium phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, potassium chloride and water for injections. BIMERVAX LP.8.1 contains potassium, sodium and polysorbate (see section 2).

## **What BIMERVAX LP.8.1 looks like and contents of the pack**

The vaccine is a white homogeneous emulsion for injection.

0.5 mL of emulsion in a pre-filled syringe (type I glass) with a plunger stopper (chlorobutyl rubber) and an integrated tip cap (polyisoprene rubber) without needle.

Each pre-filled syringe contains 1 dose of 0.5 mL

Pack sizes: 1 or 10 pre-filled syringes.

## **Marketing Authorisation Holder**

Hipra Human Health, S.L.U.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

## **Manufacturer**

Laboratorios Hipra, S.A.  
Avda. la Selva, 135  
17170 Amer (Girona)  
SPAIN

**This leaflet was last revised in 05/2026**

## **Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<https://www.ema.europa.eu>

Scan the code with a mobile device to get the package leaflet in different languages.



Or visit the URL: [www.hipracovidvaccine.com](http://www.hipracovidvaccine.com)

---

## **The following information is intended for healthcare professionals only:**

Administer BIMERVAX LP.8.1 intramuscularly, preferably into the deltoid muscle of the upper arm.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

### Handling instructions and administration

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

This vaccine should be handled by a healthcare professional using aseptic techniques to ensure the sterility of each dose.

#### *Preparation for use*

- The vaccine comes ready to use.
- Unopened vaccine should be stored at 2 °C to 8 °C and kept within the outer carton to protect from light.
- Immediately prior to use, remove the pre-filled syringe from the outer carton.

#### *Inspect the pre-filled syringe*

- Gently swirl the pre-filled syringe before the dose withdrawal. Do not shake.
- Before use, check the tightness of the closing system.
- Each pre-filled syringe contains a white homogeneous emulsion.
- Visually inspect the vaccine for particulate matter and/or discolouration prior to administration. Do not administer the vaccine if any of these are present.
- Do not administer the vaccine if the pre-filled syringe is damaged.

#### *Administer the vaccine*

- Needles are not included in the pre-filled syringe cartons.
- Use a sterile needle of appropriate gauge for intramuscular injection.
- With the tip cap upright, remove the tip cap by twisting counterclockwise until it releases. Remove the cap in a slow, steady motion. Do not pull on it while turning.
- Attach the needle by twisting in a clockwise direction until the needle locks on the syringe.
- Uncap the needle when ready for administration.
- Administer the entire dose intramuscularly.

#### *Disposal*

- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.